Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
January 09, 2023 08:00 ET
|
Xenon Pharmaceuticals Inc.
XEN1101 Phase 3 Epilepsy Program Ongoing in Focal Onset Seizures and Recently Initiated in Primary Generalized Tonic Clonic Seizures Strong financial position expected to fully support XEN1101...
Xenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 16:01 ET
|
Xenon Pharmaceuticals Inc.
BURNABY, British Columbia, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at...
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
December 02, 2022 08:30 ET
|
Xenon Pharmaceuticals Inc.
Company Presents Additional Positive Data from Open Label Extension of Phase 2b ‘X-TOLE’ Clinical Trial for Focal Onset Seizures XEN1101 Phase 3 Program to be Showcased at Scientific Exhibit Taking...
Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022
November 30, 2022 16:01 ET
|
Xenon Pharmaceuticals Inc.
BURNABY, British Columbia, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate...
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
November 09, 2022 16:30 ET
|
Xenon Pharmaceuticals Inc.
BURNABY, British Columbia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon’s...
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022 16:01 ET
|
Xenon Pharmaceuticals Inc.
XEN1101 Phase 3 program launched with initiation of X-TOLE2 clinical trial Strong financial position of approximately $752 million to fully support XEN1101 Phase 3 program development and expected...
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary
November 07, 2022 08:30 ET
|
Xenon Pharmaceuticals Inc.
BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea...
Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures
November 03, 2022 08:30 ET
|
Xenon Pharmaceuticals Inc.
BURNABY, British Columbia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the launch of its XEN1101 Phase...
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update
November 01, 2022 16:01 ET
|
Xenon Pharmaceuticals Inc.
BURNABY, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter...
Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
September 01, 2022 16:01 ET
|
Xenon Pharmaceuticals Inc.
BURNABY, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will...